Sara Kochanny
0000-0003-3755-1175
University of Chicago Medical Center
2 papers found
Refreshing results…
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study
A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Missing publications? Search for publications with a matching author name.